The Time To Buy Chinook Therapeutics Inc. (NASDAQ: KDNY) Is Now – Marketing Sentinel
Home  »  Science   »  The Time To Buy Chinook Therapeutics Inc. (NASDAQ:...

The Time To Buy Chinook Therapeutics Inc. (NASDAQ: KDNY) Is Now

During the last session, Chinook Therapeutics Inc. (NASDAQ:KDNY)’s traded shares were 0.38 million, with the beta value of the company hitting 0.10. At the end of the trading day, the stock’s price was $13.97, reflecting an intraday gain of 6.56% or $0.86. The 52-week high for the KDNY share is $19.85, that puts it down -42.09 from that peak though still a striking 24.98% gain since the share price plummeted to a 52-week low of $10.48. The company’s market capitalization is $791.12M, and the average trade volume was 327.60K shares over the past three months.

Chinook Therapeutics Inc. (KDNY) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.50. KDNY has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.79.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Chinook Therapeutics Inc. (NASDAQ:KDNY) trade information

Chinook Therapeutics Inc. (KDNY) registered a 6.56% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 6.56% in intraday trading to $13.97 this Friday, 05/13/22, hitting a weekly high. The stock’s 5-day price performance is 2.42%, and it has moved by -11.64% in 30 days. Based on these gigs, the overall price performance for the year is -5.93%.

The consensus price target of analysts on Wall Street is $31.83, which implies an increase of 56.11% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $25.00 and $40.00 respectively. As a result, KDNY is trading at a discount of -186.33% off the target high and -78.95% off the low.

Chinook Therapeutics Inc. (KDNY) estimates and forecasts

Statistics show that Chinook Therapeutics Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Chinook Therapeutics Inc. (KDNY) shares have gone down -13.12% during the last six months, with a year-to-date growth rate less than the industry average at -63.35% against 9.40. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to grow 36.30% this quarter and then jump 28.40% in the quarter after that. In the rating firms’ projections, revenue will decrease -52.80% compared to the previous financial year.

As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $827k and $351k respectively.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 20.20%. While earnings are projected to return 63.60% in 2022, the next five years will return 9.00% per annum.

KDNY Dividends

Chinook Therapeutics Inc. is due to release its next quarterly earnings between April 05 and April 11. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Chinook Therapeutics Inc. (NASDAQ:KDNY)’s Major holders

Chinook Therapeutics Inc. insiders own 6.79% of total outstanding shares while institutional holders control 66.71%, with the float percentage being 71.57%. Samsara BioCapital, LLC is the largest shareholder of the company, while 135 institutions own stock in it. As of Sep 29, 2021, the company held over 3.38 million shares (or 7.49% of all shares), a total value of $43.09 million in shares.

The next largest institutional holding, with 2.54 million shares, is of Blackrock Inc.’s that is approximately 5.63% of outstanding shares. At the market price on Sep 29, 2021, these shares were valued at $32.38 million.

Also, the Mutual Funds coming in first place with the largest holdings of Chinook Therapeutics Inc. (KDNY) shares are Fidelity Select Portfolios – Biotechnology and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF. Data provided on Oct 30, 2021 indicates that Fidelity Select Portfolios – Biotechnology owns about 1.02 million shares. This amounts to just over 2.25 percent of the company’s overall shares, with a $10.91 million market value. The same data shows that the other fund manager holds slightly less at 0.81 million, or about 1.80% of the stock, which is worth about $10.36 million.

Leave a Comment

Your email address will not be published.

On Key

Related Posts